

Amgen completed its acquisition of Immunex Corporation on July 15, 2002. This archived Immunex press releases is provided for reference only.

FOR IMMEDIATE RELEASE, July 13, 2001

The "Immunex All Stars" Celebrate 20 Years of Breakthrough Science

Immunex Corporation Launches ImmunexAllStars.com Highlighting the Best that Biotechnology Has to Offer molecule Represents Potential Expansion of Inflammatory Franchise

SEATTLE - Today marks the 20th anniversary of one of the largest biotechnology companies in the world, Immunex (Nasdaq: IMNX), a leader in the technology revolution in medicine. In recognition of this milestone, Immunex has introduced an All Star line up of employees and patients who are fighting against illness and winning.

One of those "Immunex All Stars," 17-year-old Katie Emmerson, can now walk - and throw out a first pitch - thanks to a breakthrough drug from Immunex. After 10 years battling her disease, Katie now leads an active life.

"Katie and I have had the pleasure of meeting many of the employees of Immunex," said Patti Emmerson, Katie's mother. "Today, Katie swims, goes to dances, and enjoys cooking. Thanks to Immunex, I can hug my daughter without causing her pain and there are tons of hugs for all of these accomplishments that so many might take for granted."

The Immunex All Star anniversary celebration will hit the big leagues today with Immunex night at the Seattle Mariners game. The event will feature Jeff LaMaine throwing out the first pitch of the game. Jeff was recently treated with the company's first biopharmaceutical product LEUKINE® (sargramostim), a white blood cell stimulant, which was launched by the company 10 years ago.

"We developed the Immunex All Stars program as a way of recognizing the extraordinary achievements of patients, employees and others involved in creating the future of medicine," said Ed Fritzky, Immunex chairman, CEO and president. "These 20 All Stars highlight the best that biotechnology has to offer."

The Immunex All Stars:

Katie Emmerson: A patient who has moved from a wheelchair to the pitcher's mound due to a breakthrough therapy from Immunex;

Debbie Salazar: A patient who has regained some of the independence she cherished after starting therapy on an Immunex drug;

Susan Erb: Building something bigger than a baseball stadium for Immunex as the vice president of corporate facilities and engineering;

Jeff LaMaine: Treated with an Immunex drug and staying active, even throwing the first pitch in front of thousands of people;

Kathy Thompson: Immunex employee who plays a vital role in encouraging hundreds of employees to engage in community activities;

June Eisenman: An Immunex employee who is dedicated to creating future science all stars through educational outreach;

Kerry Wolter: Believes her life has improved for the better due to the Immunex therapy she is taking;

Ron Sandelius: A real "iron man" as he is able to compete in athletic competitions again after starting therapy on an Immunex drug;

Carl March: Advancing the technology revolution for Immunex as senior vice president of information technology;

Arleen Paulino: Dedicated to expanding manufacturing capacity for breakthrough products developed by Immunex;

Joe Carlin: Living an active life again with his sons and wife after starting therapy on an Immunex drug;

Craig Smith and Ray Goodwin: Using science to give hope to thousands as the team who discovered a medical breakthrough therapy for Immunex;

Janis Wignall: Taking students from little league to the big leagues of biotech through hands-on science training of school children;

Beth Fortmueller: Immunex first-round draft pick when hired 20 years ago;

John Sims: Devoting time and energy to finding new and innovative treatments for patients in his role as senior director of molecular genetics;

Maye Fukomoto: A patient who started on an Immunex therapy and is back to bicycling to keep a sound mind and sound body;

Ann Hayes: Ann led the medical research team for all Immunex products for the last seven years;

Katie Kulzyk: Katie is a shareholder and a patient who is delighted to be able to swim and play with her kids again;

Craig Zupke: A senior staff scientist whose goal it is to move a new molecule from the bench to a therapy for patients; and

Jim Whitmore: Directs the biometrics group in establishing statistical measures that Immunex must meet to demonstrate that a product is sufficiently effective.

To learn more about the Immunex All Stars, and to learn more about entering to win a trip for two to the first game of the 2001 Major League Baseball World Series®, visit www.immunexallstars.com.

Today, Immunex markets multiple products based on immune system science innovation. Through research and scientific inquiry, the more than 1,500 people who work at Immunex are pioneering medications in rheumatoid arthritis, cancer, multiple sclerosis, and other diseases.

LEUKINE® (sargramostim)

In three prospective, randomized, double-blind placebo-controlled trials, only one adverse event

was significantly increased in patients receiving LEUKINE (n=170) vs. placebo (n=166). In the pivotal AML trial, skin-associated events were observed in 77% (n=40/52) of LEUKINE patients vs. 45% (n=21/47) of placebo patients (p=.002). Other adverse events have been reported, see full prescribing information available by calling 1-800-IMMUNEX (800-466--8639) or by visiting www.immunex.com.

In clinical trials, there were occasional reports of fluid retention, dyspnea, supraventricular tachycardia, and laboratory abnormalities (increases in creatinine, bilirubin, and liver enzymes).

Immunex Corporation is a leading biopharmaceutical company dedicated to improving lives through immune system science innovations.

NOTE: Except for the historical information contained herein, this news release contains forward-looking statements that involve substantial risks and uncertainties. Among the factors that could cause actual results or timelines to differ materially are risks associated with research and clinical development, regulatory approvals, our supply capabilities and reliance on third-party manufacturers, product commercialization, competition, litigation and other risk factors listed from time to time in reports filed by Immunex with the SEC, including but not limited to risks described under the caption "Important Factors That May Affect Our Business, Our Results of Operations and Our Stock Price" within our most recently filed Form 10-Q. The forward-looking statements contained in this news release represent our judgment as of the date of this release. Immunex undertakes no obligation to publicly update any forward-looking statements. An electronic version of this news release -- as well as additional information about Immunex of interest to investors, customers, future employees and patients -- is available on the Immunex home page at www.immunex.com.